Clinical Data, Inc.’s Cogenics Division and National Institute of Environmental Health Sciences Researchers Confirm Utility of Blood Samples for Gene Expression Analysis of Drug-Induced Liver Injury

NEWTON, Mass.--(BUSINESS WIRE)--Clinical Data, Inc. (NASDAQ:CLDA) announced today that its Cogenics® division, a leading provider of value-based genomic solutions to the healthcare and life sciences industries, has published a study with researchers from the National Institute of Environmental Health Sciences (NIEHS) confirming that gene expression data from blood samples can be used to discriminate different types of liver damage resulting from drug toxicity. This project was funded in part with Federal funds from the National Institute of Environmental Health Sciences, National Institutes of Health, under Contract No. N01-ES-25497.

Back to news